News

UBS Predicts Growth for Deutsche Telekom with Upgraded Rating

UBS Predicts Growth for Deutsche Telekom with Upgraded Rating

UBS Upgrades Deutsche Telekom to 'Buy' Rating

UBS Global Research has recently made a significant shift in its outlook for Deutsche Telekom (OTC: DTEGY), moving the stock to a 'buy' rating. This decision comes in light of recent market trends that have offered what UBS sees as an attractive entry point for investors.

Current Stock Movement

In the wake of this upgrade, shares of the well-known German telecom giant experienced a 1.5% uptick, reflecting a market response to UBS's updated stance. This bounce back follows a prior dip of roughly 6% in share price, a decline that UBS attributes primarily to cautious statements regarding the company's fourth-quarter performance and a decline in T-Mobile US (NASDAQ: TMUS) stock.

Key Factors Behind the Upgrade

UBS emphasizes that the decline in Deutsche Telekom's stock should be viewed as a buying opportunity. The analysts note that more than two-thirds of the company's earnings before interest, taxes, depreciation, and amortization (EBITDA) is generated from its operations in the United States. This exposure positions Deutsche Telekom favorably in a market that continues to show promise.

Growth Prospects

UBS forecasts an annual earnings per share growth rate of 11% for Deutsche Telekom, a figure that reflects the company’s resilience amid price competition in certain European markets. The firm has revised its price target for Deutsche Telekom to €33, an increase from the previous €31, largely thanks to favorable movements in the exchange rate.

Potential Upside Catalysts

The analysts at UBS have outlined several potential catalysts that could drive further gains for Deutsche Telekom. These include:

  • Strengthening of the US dollar
  • Optimistic projections for T-Mobile US’s performance in 2025
  • Possible adjustments to US tax regulations
  • Opportunities for mergers and acquisitions in the US telecom sector
  • Continued share buyback initiatives at Deutsche Telekom

Company's Recent History and Future Outlook

This upgrade marks a turnaround from UBS's previous downgrade to 'neutral' in September, which was influenced by heightened expectations ahead of the company's Capital Markets Day and the competitive landscape in the German mobile market. Additionally, uncertainties surrounding SoftBank's stake in Deutsche Telekom further contributed to that earlier caution.

Strategic Decisions and Leadership Stability

Following the recent Capital Markets Day, some positive indicators emerged. Notably, the company reaffirmed its commitment to maintaining a leverage ratio of 2.75x, which effectively provides about €15 billion in maneuverability for strategic decisions like increasing its stake in T-Mobile US or pursuing share repurchases.

Leadership Insights

The extension of CEO Tim Hoettges' contract beyond 2026 is viewed as a positive marker for the company's long-term strategic direction, reflecting stability at the leadership level.

Deutsche Telekom’s Market Position

Despite facing competitive pressures in the German mobile space, Deutsche Telekom’s foundational strengths remain intact. The company holds a dominant position in the German broadband market, with fixed-line services comprising an impressive 70% of its revenue. This solid foundation has enabled the company to benefit from rising pricing in both wholesale and retail segments.

Forecasts and Financial Expectation

UBS anticipates modest growth for Deutsche Telekom’s operations in Germany, projecting service revenue increases of 1.7% annually and EBITDA growth of 2.9% from 2024 to 2027.

Outlook for T-Mobile US and Broader US Telecom Market

UBS maintains a favorable outlook for T-Mobile US, even as the company navigates some temporary challenges, including the end of public subsidies for its low-income assistance program. Despite these setbacks, the overall US telecom market is expected to thrive, marked by limited competition and the promise of future price hikes.

Shareholder Returns and Financial Commitment

Investors can anticipate a solid return on investment, with UBS projecting an 11% annual growth in earnings per share, likely leading to an increase in dividends. The expected dividend hike to €0.90 in 2024 suggests a robust intent to reward shareholders.

Conclusion and Market Considerations

While Deutsche Telekom displays a defensive business structure with stable double-digit EPS growth at appealing valuations, certain risks remain—particularly concerned with SoftBank's stake, which could lead to market fluctuations. However, with strategic insights and a focus on shareholder value, Deutsche Telekom appears well-positioned for future success.

Frequently Asked Questions

What motivated UBS to upgrade Deutsche Telekom's stock rating?

The upgrade was motivated by the recent stock price pullback and the company's strong exposure to the US market, which positions it for growth.

How much has UBS raised the price target for Deutsche Telekom?

UBS raised its price target for Deutsche Telekom from €31 to €33, largely influenced by favorable exchange rate movements.

What factors are expected to drive growth for Deutsche Telekom?

Key growth drivers include US market exposure, earnings growth, potential mergers, and changes in US tax policy.

What is the expected annual EPS growth rate for Deutsche Telekom?

UBS forecasts an annual earnings per share growth of 11% for Deutsche Telekom.

How does Deutsche Telekom plan to reward shareholders?

The company plans to reward shareholders through dividends, with an expected hike to €0.90 in 2024, along with share repurchases worth €2 billion.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 0

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 4

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 0

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 6

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 5

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 1

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

Theravance Biopharma's YUPELRI® Receives Regulatory Green Light

Updated Category News Views 222

Theravance Biopharma's YUPELRI® Approves by China's NMPA Theravance Biopharma, Inc. (NASDAQ: TBPH) has announced a major achievement with the approval of YUPELRI® (revefenacin) by China’s National Medical Products Administration (NMPA). This landmark decision positions YUPELRI as the first once-daily nebulized long-acting muscarinic antagonist (LAMA) to be approved...

Continue Reading
Discover Passive Income Opportunities with SIX MINING's Innovative Platform

Updated Category News Views 233

Unleashing Passive Income Potential with SIX MINING SIX MINING is an innovative cryptocurrency investment platform established in the UK that is dedicated to creating an accessible environment for those interested in crypto mining. It aims to provide a green energy approach, allowing individuals from all backgrounds to benefit financially through easy-to-navigate...

Continue Reading
KARNO Linear Generator Gains Approval Under California RPS

Updated Category News Views 166

Hyliion Holdings Corp. (NYSE: HYLN) got its KARNO linear generator approved under California's Renewables Portfolio Standard (RPS), and that's no small feat. This move aligns perfectly with California's aggressive climate goals as it pushes for 60% of retail electricity sales to come from renewables by 2030, ramping up to full carbon neutrality by 2045. But let’s peel...

Continue Reading
nCino Reports Strong Preliminary Q1 Fiscal Year 2026 Results

Updated Category News Views 228

nCino Exceeds Revenue Expectations for First Quarter nCino, Inc. (NASDAQ: NCNO), a prominent provider of cutting-edge banking solutions, has proudly announced that its preliminary financial results for the recently concluded first quarter have surpassed the upper limits of the guidance it previously provided. These results encompass Total Revenues, Subscription Revenues,...

Continue Reading
Stantec's Strategic Role in Developing New Commercial Port

Updated Category News Views 123

Stantec's Role in the Development of a Modern Commercial Port Stantec is set to embark on an ambitious project to design and engineer a new commercial port of entry alongside design-build partners, Hensel Phelps and Jones Studio. This partnership has been awarded a significant contract worth $274.7 million, highlighting Stantec's expertise in transforming infrastructure...

Continue Reading